Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05690386 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Trial to Investigate Different Doses of Lonapegsomatropin Compared to Somatropin in Individuals With Turner Syndrome

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. 2 versions Re-verified since Dec 19, 2025, no change to tracked fieldsv26-v27
  2. Primary completion date changed from estimate of Dec 2024 to Oct 18, 2024v25
  3. Study completion date: Jun 2026 to Dec 2027
    • Secondary endpoints: details revised at 4 of 4 entries
    v24
  4. Re-verified, no change to tracked fieldsv23
  5. Trial status: Recruiting to Active, Not Recruiting
    • Study sites: 24 to 19
    • Primary completion date: Oct 2025 to Dec 2024
    • Study completion date: Oct 2025 to Jun 2026
    v22
Show 20 earlier versionsHide 20 earlier versions
  1. Site details revised at 1 of 24 sitesv21
  2. Site details revised at 1 of 24 sitesv20
  3. Site details revised at 2 of 24 sitesv19
  4. Site details revised at 1 of 24 sitesv18
  5. Site details revised at 1 of 24 sitesv17
  6. Site details revised at 1 of 24 sitesv16
  7. Study sites: 23 to 24v15
  8. Study sites: 22 to 23v14
  9. Site details revised at 1 of 22 sitesv13
  10. Study sites: 21 to 22v12
  11. Site details revised at 2 of 21 sitesv11
  12. Study sites: 19 to 21v10
  13. Site details revised at 3 of 19 sitesv9
  14. Site details revised at 3 of 19 sitesv8
  15. Study sites: 18 to 19v7
  16. Site details revised at 1 of 18 sitesv6
  17. Site details revised at 1 of 18 sitesv5
  18. Start date changed from estimate of Jan 2023 to Feb 15, 2023
    • Eligibility criteria expanded, about 21 words
    • Site details revised at 1 of 18 sites
    v4
  19. Trial status: Not Yet Recruiting to Recruiting
    • Site details revised at 18 of 18 sites
    v3
  20. Interventions: Lonapegsomatropin (Biological), Somatropin (Device) to Lonapegsomatropin (Biological), Somatropin (Drug)
    • Study title shortened, about 19 words
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
A 104 week dose finding open label trial followed by an optional 78 week open label extension of lonapegsomatropin, a long-acting growth hormone product, administered once-a-week versus daily somatropin product in prepubertal individuals with Turner syndrome. Approximately 48 individuals (12 individuals per arm) will be randomized to receive one of three doses of lonapegsomatropin or a daily injection of somatropin. This is a trial that will be conducted in the United States.
Trial Details
NCT Number NCT05690386
Lead Sponsor Ascendis Pharma Endocrinology Division A/S
Conditions
(from sponsor)		 Turner Syndrome
Related terms Turner Syndrome
Enrollment 48 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov